155 results on '"Navenot, Jean-Marc"'
Search Results
2. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial
3. Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial
4. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma
5. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
6. Data from Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma
7. Figures S1-S7 from Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma
8. Preliminary clinical outcomes of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in patients with advanced urothelial cancer.
9. Safety and efficacy from the phase 1 SURPASS trial of ADP-A2M4CD8, a next-generation T-cell receptor T-cell therapy, in patients with advanced esophageal, esophagogastric junction, or gastric cancer.
10. Abstract LB001: Identifying MAGE-A4-positive tumors for SPEAR T-cell therapies in HLA-A*02-eligible patients
11. Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors
12. Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer
13. 376 Radiation sub-study to characterize safety and tolerability of low-dose radiation in combination with afami-cel in patients with advanced cancers (NCT03132922)
14. 373 Enhancement of TCR-engineered T-cells targeting MAGE-A4 antigen by co-expression of CD8α and inhibition of AKT signaling during ex vivo T-cell expansion
15. Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists
16. Autologous T cell therapy for MAGE-A4+solid cancers in HLA-A*02+patients: a phase 1 trial
17. 285 Phase I clinical trial evaluating the safety of ADP-A2M10 in patients with MAGE-A10+ head and neck, melanoma, or urothelial tumors
18. 379 Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor
19. 278 Phase I clinical trial evaluating the safety of ADP-A2M10 SPEAR T-cells in patients with MAGE-A10+advanced non-small cell lung cancer
20. Structure–activity relationship study on small peptidic GPR54 agonists
21. Phase I dose escalation and expansion trial to assess the safety and efficacy of ADP-A2M4 SPEAR T cells in advanced solid tumors.
22. Requirement of KISS1 Secretion for Multiple Organ Metastasis Suppression and Maintenance of Tumor Dormancy
23. Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma
24. Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma
25. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
26. Characterization of the receptor binding residues of kisspeptins by positional scanning using peptide photoaffinity probes
27. Abstract LB-083: Phase I study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma
28. Pilot study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma.
29. IMCT-15PILOT STUDY OF T CELLS REDIRECTED TO EGFRvIII WITH A CHIMERIC ANTIGEN RECEPTOR IN PATIENTS WITH EGFRvIII+ GLIOBLASTOMA
30. Heme Oxygenase-1 Gene Promoter Polymorphism Is Associated With the Development of Necrotizing Acute Pancreatitis
31. Expression and distribution of complement regulatory proteins in Duchenne Muscular Dystrophy, Polymyositis, and X-linked Vacuolated myopathy
32. Characterization of Constitutively Active Mutants of G Protein-Coupled Receptors
33. Paradoxical Downregulation of CXC Chemokine Receptor 4 Induced by Polyphemusin II-Derived Antagonists
34. The metastasis suppressor KISS1 lacks antimetastatic activity in the C8161.9 xenograft model of melanoma
35. MicroRNA Profiling in Lung Cancer Reveals New Molecular Markers for Diagnosis
36. Heme Oxygenase-1 Gene Promoter Polymorphism and Acute Pancreatitis
37. Activation of Rho and Rho-Associated Kinase by GPR54 and KiSS1 Metastasis Suppressor Gene Product Induces Changes of Cell Morphology and Contributes to Apoptosis
38. KiSS1 Metastasis Suppressor Gene Product Induces Suppression of Tyrosine Kinase Receptor Signaling to Akt, Tumor Necrosis Factor Family Ligand Expression, and Apoptosis
39. Physical association of GPR54 C-terminal with protein phosphatase 2A
40. Heat Shock Response in CHO Mammalian Cells Is Controlled by a Nonlinear Stochastic Process
41. Association of Nucleophosmin Negatively Regulates CXCR4-Mediated G Protein Activation and Chemotaxis
42. SAR and QSAR Studies on the N-Terminally Acylated Pentapeptide Agonists for GPR54
43. Design and synthesis of downsized metastin (45–54) analogs with maintenance of high GPR54 agonistic activity
44. Kisspeptin-10-Induced Signaling of GPR54 Negatively Regulates Chemotactic Responses Mediated by CXCR4: a Potential Mechanism for the Metastasis Suppressor Activity of Kisspeptins
45. Heat shock response in CHO mammalian cells is controlled by a nonlinear stochastic process
46. Constitutive Activation of CCR5 and CCR2 Induced by Conformational Changes in the Conserved TXP Motif in Transmembrane Helix 2
47. S‐protein is expressed in necrotic fibers in Duchenne muscular dystrophy and polymyositis
48. CXCR4–SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion
49. A Point Mutation That Confers Constitutive Activity to CXCR4 Reveals That T140 Is an Inverse Agonist and That AMD3100 and ALX40-4C Are Weak Partial Agonists
50. Characterization of Constitutively Active Mutants of G Protein-Coupled Receptors.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.